A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants

A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.

NCT00192179 ·Status: COMPLETED ·Phase: PHASE2

Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Children

NCT00192244 ·Status: COMPLETED ·Phase: PHASE3

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults

NCT00192192 ·Status: COMPLETED ·Phase: PHASE3

Trial of the Safety, Transmissibility, and Phenotypic and Genotypic Stability of Influenza Virus Vaccine,(CAIV-T), in Children Who Attend Day Care. (Final Report Version 2.0)

NCT00192361 ·Status: COMPLETED ·Phase: PHASE3

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)

NCT00192231 ·Status: COMPLETED ·Phase: PHASE3

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older

NCT00192153 ·Status: COMPLETED ·Phase: PHASE2

Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older

NCT00217230 ·Status: COMPLETED ·Phase: PHASE3

Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza

NCT00192413 ·Status: COMPLETED ·Phase: PHASE3

Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months

NCT00192166 ·Status: COMPLETED ·Phase: PHASE2

Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma

NCT00192257 ·Status: COMPLETED ·Phase: PHASE3

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

NCT00192309 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children

NCT00344305 ·Status: COMPLETED ·Phase: PHASE2

Immunogenicity and Safety Following a Single Dose of Influenza Vaccines in Healthy Children Who Received Either One or the Other Vaccine (an Adjuvanted Sub-unit Influenza Vaccine and a Non-adjuvanted Split Virion Influenza Vaccine) in the Previous V70P2 Study

NCT00644540 ·Status: COMPLETED ·Phase: PHASE2

Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to <36 Months

NCT00311428 ·Status: COMPLETED ·Phase: PHASE4

Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age

NCT01857206 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications

NCT01998477 ·Status: COMPLETED ·Phase: PHASE3

Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months

NCT00649883 ·Status: COMPLETED ·Phase: PHASE2

Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years

NCT00599443 ·Status: COMPLETED ·Phase: PHASE1

Sanofi Pasteur, TIV + H1N1, Pediatric Population

NCT00943202 ·Status: COMPLETED ·Phase: PHASE2

Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines

NCT00644059 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years

NCT02212106 ·Status: COMPLETED ·Phase: PHASE4

Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old

NCT00464672 ·Status: COMPLETED ·Phase: PHASE3

Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults

NCT02148328 ·Status: COMPLETED ·Phase: PHASE1

Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children

NCT00408395 ·Status: COMPLETED ·Phase: PHASE2

Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008

NCT00511914 ·Status: COMPLETED ·Phase: PHASE3